{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:27:42Z","timestamp":1793636862219,"version":"4.5.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["20230484483"],"award-info":[{"award-number":["20230484483"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004480","name":"Natural Science Foundation of Shanxi Province","doi-asserted-by":"publisher","award":["20210302123258"],"award-info":[{"award-number":["20210302123258"]}],"id":[{"id":"10.13039\/501100004480","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172923"],"award-info":[{"award-number":["82172923"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81372739"],"award-info":[{"award-number":["81372739"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82573247"],"award-info":[{"award-number":["82573247"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ijbiomac.2026.154763","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:31:23Z","timestamp":1791318683000},"page":"154763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["PDZ domain containing 1 sensitizes renal cancer cells to everolimus via inhibiting phosphatase and tensin homolog phosphorylation-mediated mTOR pathway activation"],"prefix":"10.1016","volume":"385","author":[{"given":"Yinong","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingshi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanfeng","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duiping","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqi","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junfang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ijbiomac.2026.154763_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18081774","article-title":"Epigenome aberrations: emerging driving factors of the clear cell renal cell carcinoma","volume":"18","author":"Mehdi","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.154763_bb0010","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2025.06.005","article-title":"Epidemiology of Renal Cancer: Incidence, Mortality, Survival, Genetic Predisposition, and Risk Factors","volume":"88","author":"Larcher","year":"2025","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.154763_bb0015","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1186\/s12885-025-13902-w","article-title":"Global, regional, and national burden of kidney cancer and attributable risk factors in adults aged 65 years and older from 1990 to 2021 and projections to 2040","volume":"25","author":"Zhou","year":"2025","journal-title":"BMC Cancer"},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.154763_bb0020","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/iju.12147","article-title":"Role of vaccine therapy for renal cell carcinoma in the era of targeted therapy","volume":"20","author":"Yoshimura","year":"2013","journal-title":"Int. J. Urol."},{"issue":"22","key":"10.1016\/j.ijbiomac.2026.154763_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/cells14221781","article-title":"Recent Advances in nccRCC Classification and Therapeutic Approaches","volume":"14","author":"Wang","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.ijbiomac.2026.154763_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217514","article-title":"Osalmid sensitizes clear cell renal cell carcinoma to navitoclax through a STAT3\/BCL-XL pathway","volume":"613","author":"Xue","year":"2025","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.154763_bb0035","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2013.09.038","article-title":"Targeted therapy in metastatic renal carcinoma","volume":"343","author":"Mattei","year":"2014","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.154763_bb0040","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/ijc.28023","article-title":"Targeting PI3K and mTORC2 in metastatic renal cell carcinoma: new strategies for overcoming resistance to VEGFR and mTORC1 inhibitors","volume":"133","author":"Figlin","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.154763_bb0045","article-title":"Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions","volume":"16","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.154763_bb0050","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00280-013-2339-y","article-title":"A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)","volume":"73","author":"Molina","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.154763_bb0055","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1111\/cas.13169","article-title":"Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus","volume":"108","author":"Matsuki","year":"2017","journal-title":"Cancer Sci."},{"issue":"15","key":"10.1016\/j.ijbiomac.2026.154763_bb0060","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.154763_bb0065","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/iju.13776","article-title":"Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study","volume":"25","author":"Matsubara","year":"2018","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.ijbiomac.2026.154763_bb0070","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.omtn.2019.01.001","article-title":"ERK Inhibitor Enhances Everolimus Efficacy through the Attenuation of dNTP Pools in Renal Cell Carcinoma","volume":"14","author":"Zou","year":"2019","journal-title":"Mol Ther Nucleic Acids"},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.154763_bb0075","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1158\/1535-7163.MCT-17-1299","article-title":"Resistance to Systemic Therapies in Clear Cell Renal Cell Carcinoma: Mechanisms and Management Strategies","volume":"17","author":"Makhov","year":"2018","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.154763_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11060830","article-title":"Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor","volume":"11","author":"Mollica","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.154763_bb0085","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-021-00571-x","article-title":"PTEN suppresses tumorigenesis by directly dephosphorylating Akt","volume":"6","author":"Bu","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.154763_bb0090","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41580-018-0015-0","article-title":"The functions and regulation of the PTEN tumour suppressor: new modes and prospects","volume":"19","author":"Lee","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.154763_bb0095","first-page":"823","article-title":"Migration of renal tumor cells depends on dephosphorylation of Shc by PTEN","volume":"38","author":"Schneider","year":"2011","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.154763_bb0100","doi-asserted-by":"crossref","first-page":"7353","DOI":"10.1038\/ncomms8353","article-title":"Epstein-Barr virus-encoded microRNA BART1 induces tumour metastasis by regulating PTEN-dependent pathways in nasopharyngeal carcinoma","volume":"6","author":"Cai","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2026.154763_bb0105","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.biopha.2018.08.127","article-title":"Scutellarin inhibits human renal cancer cell proliferation and migration via upregulation of PTEN","volume":"107","author":"Deng","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.154763_bb0110","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.7150\/ijbs.68980","article-title":"OTUD1 stabilizes PTEN to inhibit the PI3K\/AKT and TNF-alpha\/NF-kappaB signaling pathways and sensitize ccRCC to TKIs","volume":"18","author":"Liu","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.154763_bb0115","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/annonc\/mdi182","article-title":"Akt activation in renal cell carcinoma: contribution of a decreased PTEN expression and the induction of apoptosis by an Akt inhibitor","volume":"16","author":"Hara","year":"2005","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.154763_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0056185","article-title":"High-resolution mutational profiling suggests the genetic validity of glioblastoma patient-derived pre-clinical models","volume":"8","author":"Yost","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijbiomac.2026.154763_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2013.00240","article-title":"Genomic rearrangements of PTEN in prostate cancer","volume":"3","author":"Phin","year":"2013","journal-title":"Front. Oncol."},{"issue":"31","key":"10.1016\/j.ijbiomac.2026.154763_bb0130","doi-asserted-by":"crossref","first-page":"31916","DOI":"10.18632\/oncotarget.5577","article-title":"Phosphorylation and inactivation of PTEN at residues Ser380\/Thr382\/383 induced by Helicobacter pylori promotes gastric epithelial cell survival through PI3K\/Akt pathway","volume":"6","author":"Yang","year":"2015","journal-title":"Oncotarget"},{"issue":"14","key":"10.1016\/j.ijbiomac.2026.154763_bb0135","doi-asserted-by":"crossref","first-page":"5010","DOI":"10.1128\/MCB.20.14.5010-5018.2000","article-title":"Phosphorylation of the PTEN tail regulates protein stability and function","volume":"20","author":"Vazquez","year":"2000","journal-title":"Mol. Cell. Biol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.154763_bb0140","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1073\/pnas.0811212106","article-title":"A phosphorylation-dependent intramolecular interaction regulates the membrane association and activity of the tumor suppressor PTEN","volume":"106","author":"Rahdar","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ijbiomac.2026.154763_bb0145","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.canlet.2019.03.043","article-title":"Loss of PDZK1 expression activates PI3K\/AKT signaling via PTEN phosphorylation in gastric cancer","volume":"453","author":"Zhao","year":"2019","journal-title":"Cancer Lett."},{"issue":"35","key":"10.1016\/j.ijbiomac.2026.154763_bb0150","doi-asserted-by":"crossref","first-page":"14164","DOI":"10.1073\/pnas.1211962109","article-title":"Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240","volume":"109","author":"Fenton","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.154763_bb0155","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/annonc\/mdp600","article-title":"Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma","volume":"21","author":"Tsavachidou-Fenner","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.154763_bb0160","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ebiom.2016.12.003","article-title":"Low level of PDZ domain containing 1 (PDZK1) predicts poor clinical outcome in patients with clear cell renal cell carcinoma","volume":"15","author":"Zheng","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijbiomac.2026.154763_bb0165","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinformatics"},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.154763_bb0170","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001130","article-title":"The SR-BI partner PDZK1 facilitates hepatitis C virus entry","volume":"6","author":"Eyre","year":"2010","journal-title":"PLoS Pathog."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.154763_bb0175","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1111\/cas.16228","article-title":"YTHDF3 phase separation regulates HSPA13-dependent clear cell renal cell carcinoma development and immune evasion","volume":"115","author":"Dai","year":"2024","journal-title":"Cancer Sci."},{"issue":"22","key":"10.1016\/j.ijbiomac.2026.154763_bb0180","doi-asserted-by":"crossref","first-page":"4404","DOI":"10.1038\/s41388-020-1297-1","article-title":"Long noncoding RNA PENG upregulates PDZK1 expression by sponging miR-15b to suppress clear cell renal cell carcinoma cell proliferation","volume":"39","author":"Qi","year":"2020","journal-title":"Oncogene"},{"issue":"44","key":"10.1016\/j.ijbiomac.2026.154763_bb0185","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1038\/onc.2017.199","article-title":"PDZK1 inhibits the development and progression of renal cell carcinoma by suppression of SHP-1 phosphorylation","volume":"36","author":"Tao","year":"2017","journal-title":"Oncogene"},{"issue":"8016","key":"10.1016\/j.ijbiomac.2026.154763_bb0190","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.154763_bb0195","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-13-152","article-title":"HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A","volume":"13","author":"Juengel","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.154763_bb0200","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ymeth.2014.10.015","article-title":"Kinases, tails and more: regulation of PTEN function by phosphorylation","volume":"77-78","author":"Fragoso","year":"2015","journal-title":"Methods"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.154763_bb0205","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/mt.2014.202","article-title":"Exosome-mediated delivery of the intrinsic C-terminus domain of PTEN protects it from proteasomal degradation and ablates tumorigenesis","volume":"23","author":"Ahmed","year":"2015","journal-title":"Mol. Ther."},{"issue":"1\u20133","key":"10.1016\/j.ijbiomac.2026.154763_bb0210","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0014-5793(02)03274-X","article-title":"Direct identification of PTEN phosphorylation sites","volume":"528","author":"Miller","year":"2002","journal-title":"FEBS Lett."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.154763_bb0215","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/0008-5472.CAN-23-1730","article-title":"PTEN Lipid Phosphatase Activity Suppresses Melanoma Formation by Opposing an AKT\/mTOR\/FRA1 Signaling Axis","volume":"84","author":"Xu","year":"2024","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.ijbiomac.2026.154763_bb0220","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1158\/0008-5472.CAN-23-2781","article-title":"The DRAP1\/DR1 Repressor Complex Increases mTOR Activity to Promote Progression and Confer Everolimus Sensitivity in Triple-Negative Breast Cancer","volume":"84","author":"Huang","year":"2024","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.154763_bb0225","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1177\/1756283X13496970","article-title":"Everolimus in the treatment of patients with advanced pancreatic neuroendocrine tumors: latest findings and interpretations","volume":"6","author":"Liu","year":"2013","journal-title":"Ther. Adv. Gastroenterol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.154763_bb0230","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1038\/s41594-021-00668-5","article-title":"The structural basis of PTEN regulation by multi-site phosphorylation","volume":"28","author":"Dempsey","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.154763_bb0235","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1042\/BJ20071068","article-title":"The C-terminus of the transmembrane mucin MUC17 binds to the scaffold protein PDZK1 that stably localizes it to the enterocyte apical membrane in the small intestine","volume":"410","author":"Malmberg","year":"2008","journal-title":"Biochem. J."},{"issue":"13","key":"10.1016\/j.ijbiomac.2026.154763_bb0240","first-page":"4985","article-title":"Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383","volume":"61","author":"Tolkacheva","year":"2001","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.154763_bb0245","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1073\/pnas.0510570103","article-title":"Tumor suppressor PTEN acts through dynamic interaction with the plasma membrane","volume":"103","author":"Vazquez","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.154763_bb0250","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1073\/pnas.97.8.4233","article-title":"Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2","volume":"97","author":"Wu","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"52","key":"10.1016\/j.ijbiomac.2026.154763_bb0255","doi-asserted-by":"crossref","first-page":"48627","DOI":"10.1074\/jbc.C100556200","article-title":"Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex","volume":"276","author":"Vazquez","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.154763_bb0260","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1007\/s00726-012-1277-z","article-title":"EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation","volume":"43","author":"Yao","year":"2012","journal-title":"Amino Acids"},{"key":"10.1016\/j.ijbiomac.2026.154763_bb0265","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","article-title":"Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer","volume":"85","author":"Yu","year":"2022","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ijbiomac.2026.154763_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102886","article-title":"Mechanisms of resistance to mTOR inhibitors","volume":"147","author":"Formisano","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ijbiomac.2026.154763_bb0275","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2119\/molmed.2011.00001","article-title":"PDZK1 is a novel factor in breast cancer that is indirectly regulated by estrogen through IGF-1R and promotes estrogen-mediated growth","volume":"19","author":"Kim","year":"2013","journal-title":"Mol. Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.154763_bb0280","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0002-9440(10)63276-2","article-title":"Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma","volume":"165","author":"Inoue","year":"2004","journal-title":"Am. J. Pathol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.154763_bb0285","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1124\/dmd.111.040295","article-title":"PDZK1 regulates breast cancer resistance protein in small intestine","volume":"39","author":"Shimizu","year":"2011","journal-title":"Drug Metab. Dispos."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.154763_bb0290","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41419-024-06502-2","article-title":"PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway","volume":"15","author":"Ma","year":"2024","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.154763_bb0295","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/s41416-024-02725-4","article-title":"PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR-\u03b2 pathway","volume":"131","author":"Wang","year":"2024","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.154763_bb0300","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/2159-8290.CD-NB2016-067","article-title":"FDA approves drug combo for kidney cancer","volume":"6","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ijbiomac.2026.154763_bb0305","doi-asserted-by":"crossref","first-page":"911","DOI":"10.2147\/DDDT.S160557","article-title":"Attenuation of everolimus-induced cytotoxicity by a protective autophagic pathway involving ERK activation in renal cell carcinoma cells","volume":"12","author":"Zeng","year":"2018","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ijbiomac.2026.154763_bb0310","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202404693","article-title":"Methuosis inducer SGI-1027 cooperates with everolimus to promote apoptosis and pyroptosis by triggering lysosomal membrane permeability in renal cancer","volume":"11","author":"Luo","year":"2024","journal-title":"Adv. Sci."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026047136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026047136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:49:20Z","timestamp":1793634560000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026047136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":62,"alternative-id":["S0141813026047136"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.154763","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PDZ domain containing 1 sensitizes renal cancer cells to everolimus via inhibiting phosphatase and tensin homolog phosphorylation-mediated mTOR pathway activation","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.154763","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"154763"}}